Cabot (CBT)
(Delayed Data from NYSE)
$109.02 USD
+1.19 (1.10%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $109.06 +0.04 (0.04%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$109.02 USD
+1.19 (1.10%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $109.06 +0.04 (0.04%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
Zacks News
Cabot (CBT) Set to Raise Global Prices of Activated Carbon
by Zacks Equity Research
Cabot (CBT) decides to raise activated carbon prices in response to escalating raw material costs and currency fluctuations.
Cabot (CBT) Up 20% in a Year: What's Driving the Stock?
by Anindya Barman
Forecast-topping earnings performance and upbeat prospects for Reinforcement Materials and Performance Chemicals segments have contributed to the run up in Cabot's (CBT) shares.
Why Is Cabot (CBT) Up 0.5% Since Last Earnings Report?
by Zacks Equity Research
Cabot (CBT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Cabot (CBT) Up 11% in 3 Months: What's Driving the Stock?
by Anindya Barman
Strong Q3 earnings and upbeat outlook for Reinforcement Materials and Performance Chemicals segments have contributed to the gain in Cabot's (CBT) shares.
Cabot (CBT) Earnings and Revenues Trump Estimates in Q3
by Zacks Equity Research
Cabot (CBT) expects strong performance across all segments in Q4.
Cabot (CBT) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Cabot (CBT) delivered earnings and revenue surprises of 2.91% and 2.75%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Cabot (CBT) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Cabot (CBT) is likely to see year-over-year revenue growth in Q3.
Cabot (CBT) Shares Up 10% QTD: What's Driving the Stock?
by Zacks Equity Research
Strong Q2 earnings and upbeat outlook for Reinforcement Materials and Performance Chemicals segments have contributed to the gain in Cabot's (CBT) shares
Cabot and Nexeo Expand Deal for Distribution in Canada
by Zacks Equity Research
Cabot's (CBT) latest move is likely to deliver meaningful benefits to its customers in Canada.
Why Cabot (CBT) Stock Might be a Great Pick
by Zacks Equity Research
Cabot (CBT) could be an interesting play for investors as it is seeing solid earnings estimate revision in addition to having a robust industry rank.
Cabot (CBT) Up 12.6% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Cabot (CBT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Cabot (CBT) to Exhibit Activated Carbon Products at ACHEMA
by Zacks Equity Research
Cabot (CBT) is set to showcase Norit range from activated carbon families at ACHEMA 2018, Germany, that will assist in catalyst application.
Cabot to Boost Global Carbon Black Capacity on Strong Demand
by Zacks Equity Research
Cabot's (CBT) latest move will expand its global carbon black capacity by more than 300,000 metric tons.
Cabot (CBT) Earnings & Revenues Surpass Estimates in Q2
by Zacks Equity Research
Solid performance in Reinforcement Materials and Performance Chemicals segments drives Cabot's (CBT) results in Q2.
Chemical Stock Earnings Slated on May 7: CBT, IFF & RYAM
by Zacks Equity Research
Chemical companies are expected to continue to gain from strategic measures this earnings season.
Cabot (CBT) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Cabot's (CBT) Q2 results are likely to benefit from continued momentum in the specialty applications and a favorable pricing environment amid higher fixed costs.
Cabot Inks Licensing Deal With Midwest Energy Emissions
by Zacks Equity Research
Cabot (CBT) inks deal with Midwest Energy Emissions, under which, it will leverage the latter's patented technologies to enhance its current portfolio of mercury removal solutions.
Cabot (CBT) Bolsters Specialty Compounds Business Globally
by Zacks Equity Research
Cabot (CBT) completes two expansion projects to increase manufacturing capacity to better serve global customers and grow in advanced polymeric materials.
Cabot to Supply New Activated Carbon for POETS Project
by Zacks Equity Research
Cabot's (CBT) Hydrodarco 4000 activated carbon being the most effective in removing PFOA has been selected by the NYSDEC to ensure safe drinking water for the residents of Town of Hoosick.
Zacks.com featured highlights include: United Natural, Western Digital, Conduent, ArcBest and Cabot
by Zacks Equity Research
Zacks.com featured highlights include: United Natural, Western Digital, Conduent, ArcBest and Cabot
Buy These 7 Low Price-to-Sales Stocks That Promise Growth
by Zacks Equity Research
A stock's price-to-sales ratio reflects how much investors are paying for each dollar of revenues generated by the company.
5 Stocks With Amazingly Low EV/EBITDA Ratios to Scoop Up
by Zacks Equity Research
We have screened value stocks based on EV/EBITDA ratio that offers a clearer picture of a company's valuation and earnings potential.
Monsanto (MON) Downgraded to Sell on Predominant Headwinds
by Zacks Equity Research
China's 25% tariffs (announced Apr 4) on agricultural products, like soybean, or headwinds, such as stiff industry rivalry, anticipated to dent Monsanto's (MON) profitability.
Monsanto Company (MON) Q2 Earnings Miss Estimates, Up Y/Y
by Zacks Equity Research
Monsanto's (MON) second-quarter fiscal 2018 earnings came in lower than the year-ago tally and missed the Zacks Consensus Estimate as well.
The Zacks Analyst Blog Highlights: Comtech Telecommunications, Curtiss-Wright, Stepan, Mellanox Technologies and Cabot
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Comtech Telecommunications, Curtiss-Wright, Stepan, Mellanox Technologies and Cabot